CERo Therapeutics Announces Trading on OTCQB Market
Rhea-AI Summary
CERo Therapeutics (OTCQB: CERO) announced its shares will begin trading on the OTCQB market under ticker CERO effective December 2, 2025 at 8:00 AM ET.
No investor action is required. The company said it is evaluating additional up‑list options, including a potential listing on a major exchange to improve liquidity and investor accessibility. Management reiterated focus on advancing its Phase 1 trial of CER‑1236 for AML, noting the starting dosage in the current cohort was increased significantly versus the prior cohort.
Positive
- Shares commence trading on OTCQB on Dec 2, 2025
- Company evaluating a potential major exchange up‑list
- Phase 1 trial cohort dosage for CER‑1236 increased
Negative
- Trading moved to OTCQB rather than a major exchange as of Dec 2, 2025
- No financial guidance or funding details provided to assess liquidity
Company’s Shares Will Continue to Trade Under Ticker CERO
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, announces its shares will be available to trade on the OTCQB market under the ticker symbol CERO effective today, December 2, 2025 as of 8:00AM ET. No action is needed on the part of investors. In the meantime, CERo continues to evaluate additional options for up-list, including, but not limited to listing on a major exchange to optimize liquidity and investor accessibility.
CERo CEO Chris Ehrlich stated, “We continue to be open for business as usual and remain committed to maximizing value for our shareholders by continuing to conduct our science and execute on our long-term business strategy. We remain focused on advancing the current cohort of our Phase 1 clinical trial of CER-1236 AML, where the starting dosage was increased significantly compared to the previous cohort. As our shares commence trading on the OTCQB, we remain committed to our shared goal of developing CER-1236.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms. The latter employ phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
FAQ
When did CERo Therapeutics start trading on OTCQB under ticker CERO?
Do CERo shareholders need to take any action after the Dec 2, 2025 OTCQB listing?
Is CERo planning to up‑list from OTCQB to a major exchange and when?
What clinical progress did CERo report about CER‑1236 on Dec 2, 2025?
Will the OTCQB listing improve liquidity for CERO shareholders immediately?
